journal article·2024-06-05

Visible-Light-Responsive Novel Ru(II)-Metallo-Antibiotics with Potential Antibiofilm and Antibacterial Activity

Arif Ali Mandal, Anjali Upadhyay, Apurba Mandal, Malay Nayak, Mohammad Sabeel K, Sudip Mukherjee, Samya Banerjee

ACS Applied Materials & Interfaces· Volume 16· Issue 22
Publisher page

Abstract

Growing challenges with antibiotic resistance pose immense challenges in combating microbial infections and biofilm prevention on medical devices. Lately, antibacterial photodynamic therapy (aPDT) is now emerging as an alternative therapy to overcome this problem. Herein, we synthesized and characterized four Ru(II)-complexes, viz ., [Ru(ph-tpy)(bpy)Cl]PF 6 ( Ru1 ), [Ru(ph-tpy)(dpq)Cl]PF 6 ( Ru2 ), [Ru(ph-tpy)(dppz)Cl]PF 6 ( Ru3 ), and [Ru(ph-tpy)(dppn)Cl]PF 6 ( Ru4 ) (where 4′-phenyl-2,2′:6′,2″-terpyridine = ph-tpy; 2,2′-bipyridine = bpy; dipyrido[3,2-f:2′,3′- h ]quinoxaline = dpq; dipyrido[3,2-a:2′,3′- c ]phenazine = dppz; and Benzo[I]dipyrido[3,2-a:2′,3′- c ]phenazine = dppn), among which Ru2–Ru4 are novel. Octahedral geometry of the complexes with a RuN 5 Cl core was evident from the crystal structure of Ru2 . Ru1–Ru4 showed an MLCT absorption band in the 450–600 nm region, useful for aPDT performances. Further, optimum triplet excited state energy and excellent photostability of Ru1–Ru4 made them good photosensitizers for aPDT. Ru1–Ru4 demonstrated enhanced antimicrobial activity on visible-light exposure (400–700 nm, 10 J cm –2 ), confirmed using different antibacterial assays. Mechanistic studies revealed that inhibition of bacterial growth was due to the generation of oxidative stress (via NADH oxidation and ROS generation) upon treatment with Ru2–Ru4, resulting in destruction of the bacterial wall. Ru2 performed best killing performance against both Gram-negative ( Escherichia coli ) and Gram-positive ( Bacillus subtilis ) bacteria when exposed to light. Ru2–Ru4, when coated on a polydimethylsiloxane (PDMS) disk, showed long-term reusability and durable antibiofilm properties. Molecular docking confirmed the efficient interaction of Ru2–Ru4 with FabH (regulates fatty acid biosynthesis of E. coli ) and PgaB (gives structural stability and helps biofilm formation of E. coli ), resulting in probable downregulation. In vivo studies with healthy Wistar rats confirmed the biocompatibility of Ru2 . This study shows that these lead complexes ( Ru2–Ru4 ) can be used as potent alternative antimicrobial agents in low concentrations toward bacterial eradication with photodynamic therapy (PDT).
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Porphyrin and Phthalocyanine Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, IIT (BHU), Varanasi, Uttar Pradesh 221005, India

School of Biomedical Engineering, IIT (BHU), Varanasi, Uttar Pradesh 221005, India

Funding

University Grants Commission · Science and Engineering Research Board · Royal Society of Chemistry · Ministry of Education, India

References (63)

Show source-provided references
1. 10.1002/advs.20210036810.1002/advs.202100368 ↗
2. 10.1056/NEJMoa130680110.1056/NEJMoa1306801 ↗
3. 10.1016/j.jiph.2021.10.02010.1016/j.jiph.2021.10.020 ↗
4. 10.1007/s40265-019-1055-210.1007/s40265-019-1055-2 ↗
5. 10.1002/cbic.20220079610.1002/cbic.202200796 ↗
6. 10.1039/C9SC06460E10.1039/C9SC06460E ↗
7. 10.1111/php.1343510.1111/php.13435 ↗
8. 10.1016/j.jinorgbio.2023.11242510.1016/j.jinorgbio.2023.112425 ↗
9. 10.2174/15701800778007739010.2174/157018007780077390 ↗
10. 10.1039/D0RA01806F10.1039/D0RA01806F ↗
11. 10.1039/D0SC04500D10.1039/D0SC04500D ↗
12. 10.1007/s00775-020-01772-510.1007/s00775-020-01772-5 ↗
13. 10.1021/acs.inorgchem.1c0303210.1021/acs.inorgchem.1c03032 ↗
14. 10.1021/acs.inorgchem.6b0245910.1021/acs.inorgchem.6b02459 ↗
15. 10.1021/acs.inorgchem.7b0110810.1021/acs.inorgchem.7b01108 ↗
16. 10.1186/s13104-023-06379-y10.1186/s13104-023-06379-y ↗
17. 10.1542/pir.36.4.16710.1542/pir.36.4.167 ↗
18. 10.1021/acsabm.9b0079410.1021/acsabm.9b00794 ↗
19. 10.1016/j.jhin.2006.05.01410.1016/j.jhin.2006.05.014 ↗
20. 10.1021/ic500521510.1021/ic5005215 ↗
21. 10.1021/acs.inorgchem.4c00650210.1021/acs.inorgchem.4c006502 ↗
22. 10.1002/(SICI)1099-0682(200001)2000:1<113::AID-EJIC113>3.0.CO;2-910.1002/(SICI)1099-0682(200001)2000:1<113::AID-EJIC113>3.0.CO;2-9 ↗
23. 10.1039/C6DT01270A10.1039/C6DT01270A ↗
24. 10.1039/C4DT02642J10.1039/C4DT02642J ↗
25. 10.1039/C5CC01865J10.1039/C5CC01865J ↗
26. 10.1039/C8DT00876K10.1039/C8DT00876K ↗
27. 10.1016/j.ejmech.2017.04.07610.1016/j.ejmech.2017.04.076 ↗
28. 10.1016/j.ccr.2018.02.01310.1016/j.ccr.2018.02.013 ↗
29. 10.1016/S0010-8545(02)00034-610.1016/S0010-8545(02)00034-6 ↗
30. 10.1039/D0CB00150C10.1039/D0CB00150C ↗
31. 10.1002/asia.20230004710.1002/asia.202300047 ↗
32. 10.1007/s11426-022-1496-010.1007/s11426-022-1496-0 ↗
33. 10.1039/D3CP02346J10.1039/D3CP02346J ↗
34. 10.1039/D2CB00247G10.1039/D2CB00247G ↗
35. 10.1021/acs.analchem.5b0210010.1021/acs.analchem.5b02100 ↗
36. 10.1021/acsabm.0c0032510.1021/acsabm.0c00325 ↗
37. 10.1039/D3DT02967K10.1039/D3DT02967K ↗
38. 10.1002/cbic.20230003310.1002/cbic.202300033 ↗
39. 10.1038/nrd100810.1038/nrd1008 ↗
40. 10.1016/j.surfcoat.2013.02.03510.1016/j.surfcoat.2013.02.035 ↗
41. 10.1021/jacs.0c0478910.1021/jacs.0c04789 ↗
42. 10.2174/092986732266614121211523610.2174/0929867322666141212115236 ↗
43. 10.1074/jbc.M115.67246910.1074/jbc.M115.672469 ↗
44. 10.1039/D3MA00378G10.1039/D3MA00378G ↗
45. 10.1021/jacs.3c0113510.1021/jacs.3c01135 ↗
46. 10.1021/jacs.9b1362010.1021/jacs.9b13620 ↗
47. 10.1016/j.ccr.2014.04.01210.1016/j.ccr.2014.04.012 ↗
48. 10.1039/C4SC03759F10.1039/C4SC03759F ↗
49. 10.1021/acs.molpharmaceut.8b0040710.1021/acs.molpharmaceut.8b00407 ↗
50. 10.1016/j.jinorgbio.2021.11146710.1016/j.jinorgbio.2021.111467 ↗
51. 10.1021/acs.inorgchem.0c0249110.1021/acs.inorgchem.0c02491 ↗
52. 10.1002/anie.20231996610.1002/anie.202319966 ↗
53. 10.1039/c3dt52879k10.1039/c3dt52879k ↗
54. 10.1039/C6SC03028A10.1039/C6SC03028A ↗
55. 10.1039/c0pp00275e10.1039/c0pp00275e ↗
56. 10.1016/j.medmic.2023.10008410.1016/j.medmic.2023.100084 ↗
57. 10.1016/j.biomaterials.2017.03.01710.1016/j.biomaterials.2017.03.017 ↗
58. 10.1021/ic500914j10.1021/ic500914j ↗
59. 10.7150/thno.781910.7150/thno.7819 ↗
60. 10.1016/j.jhazmat.2020.12378810.1016/j.jhazmat.2020.123788 ↗
61. 10.1038/nprot.2007.52110.1038/nprot.2007.521 ↗
62. 10.2147/DDDT.S7833610.2147/DDDT.S78336 ↗
63. 10.1038/s41598-021-03503-510.1038/s41598-021-03503-5 ↗